Akèy › Kadiyomiopati Ipertrofik
Etid klinik pou Kadiyomiopati Ipertrofik ap rekrite nan Etazini
16 etid pou Kadiyomiopati Ipertrofik ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Boston, MA6 etid
- Charlottesville, VA4 etid
- Cleveland, OH4 etid
- San Francisco, CA4 etid
- San Diego, CA3 etid
- Houston, TX3 etid
- New York City, NY3 etid
- Chicago, IL3 etid
Pa eta
- Illinois4 etid
- Kalifòni7 etid
- Massachusetts6 etid
- Michigan3 etid
- Minnesota3 etid
- Missouri3 etid
- New York4 etid
- North Carolina3 etid
- Ohio4 etid
- Pennsylvania3 etid
- Texas3 etid
- Virginia4 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy
Ap rekriteFaz 2
Laj 6 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT07721025A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT05489705Study of the Progression of Chronic Cardiovascular Conditions
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Aug 12, 2026 · NCT07420907Cardiovascular Multimodality Imaging Study
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Aug 10, 2026 · NCT06610019Pediatric Cardiomyopathy Mutation Analysis
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Jun 22, 2026 · NCT02432092Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 50 ak plis · Tout sèks · Mizajou Jun 4, 2026 · NCT06034405Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy
Ap rekriteFaz 4
Laj 18 a 90 · Tout sèks · Mizajou May 20, 2026 · NCT07600177A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou May 18, 2026 · NCT07023614A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease
Ap rekriteFaz 2
Laj 8 ak plis · Gason · Mizajou May 4, 2026 · NCT06092034Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM
Ap rekriteFaz 1/2
Laj 18 a 75 · Tout sèks · Mizajou Mar 19, 2026 · NCT05836259HCMR Re-Imaging Study
Ap rekriteEtid obsèvasyon
Laj 18 a 65 · Tout sèks · Mizajou Mar 18, 2026 · NCT07054073Exercise Intolerance in Non-obstructive Hypertrophic Cardiomyopathy
Ap rekrite
Laj 18 a 80 · Tout sèks · Mizajou Nov 20, 2025 · NCT05818605Mavacamten Pregnancy Surveillance Program
Ap rekriteEtid obsèvasyon
Laj 15 ak plis · Fanm · Mizajou Nov 6, 2025 · NCT05939700Large Language Models To Improve the Quality of Care of Cardiology Patients
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou May 15, 2025 · NCT06935253Real-world Patient Reported Outcomes Among Patients Treated With Camzyos
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Nov 7, 2024 · NCT06551129Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM
Ap rekriteEtid obsèvasyon
Laj 18 a 85 · Tout sèks · Mizajou Nov 6, 2024 · NCT06023186Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.